

BIOCON BIOLOGICS BELGIUM BV
BALANCE SHEET AS AT MARCH 31, 2026

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	March 31, 2026	March 31, 2025
ASSETS			
Non-current assets			
Right-of-use assets		289	378
Deferred tax asset (net)		39	-
Total non-current assets		328	378
Current assets			
Financial assets			
(i) Trade receivables	1	564	758
(ii) Cash and cash equivalents	2	381	388
Other current assets	3	25	80
Total current assets		970	1,226
TOTAL		1,298	1,604
EQUITY AND LIABILITIES			
Equity			
Equity share capital	4	17	17
Other equity	5	190	109
Total equity		207	126
Non-current liabilities			
Lease liabilities		224	310
Total Non current liabilities		224	310
Current liabilities			
Financial liabilities			
(i) Trade payables	6	389	970
(ii) Lease liabilities		86	79
Income-tax liability (net)		35	50
Provisions	7	125	66
Other current liabilities	8	232	3
Total current liabilities		867	1,168
TOTAL		1,298	1,604

BIOCON BIOLOGICS BELGIUM BV**STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2026**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

		Year ended	Year ended
	<u>Notes</u>	March 31, 2026	March 31, 2025
Income			
Revenue from operations	9	2,738	2,905
Other operating income	10	(55)	7
Total revenue		2,683	2,912
Expenses			
Employee benefits expense	11	1,772	1,835
Depreciation		89	65
Finance Costs	12	29	26
Other expenses	13	609	848
Total expenses		2,499	2,774
Profit before Exceptional Items		184	138
Exceptional Expense		54	-
Profit after Exceptional Items		131	138
Tax expense			
Current tax		89	28
Deferred Tax		(39)	28
Total tax expense		50	56
Profit for the year		81	82

BIOCON BIOLOGICS BELGIUM BV**STATEMENT OF CASH FLOWS FOR THE YEAR ENDED MARCH 31, 2026**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Year ended March 31, 2026	Year ended March 31, 2025
I Cash flows from operating activities		
Profit after tax	81	82
<u>Adjustments to reconcile profit before tax to net cash flows:</u>		
Depreciation and amortisation (net)	89	65
Unrealised foreign exchange Loss/(gain)	55	(7)
Interest expense	29	26
Tax expense	50	56
Operating profit before working capital changes	303	222
Movements in working capital		
Decrease/(Increase) in trade receivables	194	(425)
Decrease/(Increase) in loans and advances and other assets	55	(80)
(Decrease)/Increase in trade payable, other liabilities and provisions	(347)	622
Cash flow generated from operations	205	338
Direct taxes paid	(104)	(16)
Net cash flow generated from operating activities	101	322
II Cash flows generated from investing activities	-	-
III Cash flows from financing activities		
Repayment of Lease Liability	(108)	(80)
Net cash flow (used in) financing activities	(108)	(80)
IV Net (decrease)/increase in cash and cash equivalents (I + II + III)	(7)	242
V Effect of exchange differences on cash and cash equivalents held in foreign currency	-	-
VI Cash and cash equivalents at the beginning of the year	388	146
VIII Cash and cash equivalents at the end of the year (IV + V + VI)	381	388
Reconciliation of cash and cash equivalents as per statement of cash flow		
Cash and cash equivalents		
Balances with banks - on current accounts	361	388
- on deposit accounts	20	-
Cash on hand	-	-
Total cash and cash equivalents [Refer note 2]	381	388

BIOCON BIOLOGICS BELGIUM BV**Notes to financial statements for the year ended March 31, 2026**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	March 31, 2026	March 31, 2025
1. Trade receivables		
Other Receivables		
Outstanding for a period less than six months from the date they are due for payment		
Unsecured, considered good	564	758
	564	758
2. Cash and cash equivalents		
Balances with banks:		
On current accounts	361	388
Deposit accounts	20	-
	381	388
3. Other current assets		
Advance to suppliers	1	1
Prepayments	1	-
Balance with Government Authorities	23	79
	25	80
4. Share capital		
Equity share 16,500 of EUR 1 each	17	17
	17	17
5. Other equity		
Surplus in the statement of profit and loss		
Balance as per the last financial statements	109	27
Profit for the year	81	82
Net surplus in the statement of profit and loss	190	109
Total other equity	190	109
6. Trade payables	389	970
7. Provisions		
Current		
Compensated absences	125	66
	125	66
8. Other liabilities		
Current liabilities		
Statutory liabilities	232	3
	232	3

BIOCON BIOLOGICS BELGIUM BV**Notes to financial statements for the year ended March 31, 2026**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Year ended March 31, 2026	Year ended March 31, 2025
9. Revenue from operations		
Support service cross charge to Group Companies	2,738	2,905
	2,738	2,905
10. Other operating income		
Foreign exchange fluctuations, net	(55)	7
	(55)	7
11. Employee benefits expense		
Salaries, wages and bonus	1,531	1,724
Employee stock compensation expense	93	5
Staff welfare expenses	148	106
	1,772	1,835
12. Finance Costs		
Interest on lease obligation	29	26
	29	26
13. Other expenses		
Rates and taxes	33	28
Rent	(21)	64
Legal and professional fees	295	210
Repair and Maintenance	19	40
Travelling and conveyance	98	111
Sales promotion expenses	15	317
Freight outwards and clearing charges	11	20
Printing and stationery	7	12
Communication expenses	9	9
Miscellaneous expenses	143	37
	609	848